Clinical guidelines support the use of 18F- fluciclovine as an imaging option for prostate cancer recurrence or progression1,3
National Comprehensive Cancer Network® (NCCN®)1
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer Version 2.20181 state that F-18 fluciclovine PET/CT or PET/MRI should be considered as options in the clinical workup of patients with recurrence or progression of their prostate cancer.
Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
To view the full NCCN Clinical Practice Guidelines in Oncology in Prostate Cancer Version 2.2018, click here.
American Society of Clinical Oncology (ASCO)2
The ASCO Clinical Practice Guideline: Optimum Imaging Strategies for Advanced Prostate Cancer states that for patients with rising prostate-specific antigen (PSA) after local treatment who are considered suitable for salvage therapy, next generation imaging (NGI), including 18F-fluciclovine PET, should be considered.
American College of Radiology (ACR)3
The ACR Appropriateness Criteria® for Post-Treatment Follow-up of Prostate Cancer categorizes 18F-fluciclovine PET/CT skull base to midthigh as “usually appropriate” for post treatment follow up in the following situations:
- Variant 1: Prostate cancer follow-up. Status post radical prostatectomy. Clinical concern for residual or recurrent disease.
- Variant 2: Prostate cancer follow-up. Clinical concern for residual or recurrent disease after nonsurgical local and pelvic treatments.
- Variant 3: Metastatic prostate cancer treated by systemic therapy (androgen deprivation therapy [ADT], chemotherapy, immunotherapy). Follow-up.
To view the full ACR Appropriateness Criteria® for Post-Treatment Follow-up of Prostate Cancer, click here.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Guideline for Prostate Cancer (Version 2.2018). © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed 03/08/2018. To view the most recent and complete version of the guideline, go to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- Trabulsi EJ et al. Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. J Clin Oncol. 2020 Jan 15. Accessed 03/25/2020.
- Froemming AT, Verma S, Eberhardt SC, et al., for the Expert Panel on Urologic Imaging. American College of Radiology, ACR Appropriateness Criteria® (Post-treatment Follow-up of Prostate Cancer). © 2017 American College of Radiology. https://acsearch.acr.org/docs/69369/Narrative/. Accessed 03/01/2018.